retatrutide phase 2 type 2 diabetes weight loss 2024 may be the next big thing in obesity medicine, but it is not here yet. After the ADA meeting this week, there is a lot of excitement around the data. Bigger Eli Lilly infiltrates anti-obesity market

Genetic predispositions in GLP-1 receptor and bile acid metabolism pathways can provide additional decision-support context

Association of telomere shortening in myocardium with heart weight gain and cause of death

The primary objective of this research is to evaluate the impact of increased levels of dietary Lcarnitine on egg production, egg weight, and hatching traits of broiler breeder hen from 32 to 36 weeks of age

There was also a greater reduction in waist circumference (-6.28 cm), BMI (-2.53 kg/m2), and weight (-4.33 kg) than in controls when liraglutide was added alongside other medication or taken alone [18]

doi: 10.1042/CS20180891, 47

Decreases in binge eating behaviors This 2024 review also found that GLP-1 medications may help reduce binge eating by lowering appetite and food cravings